Skip to main content
SpringerLink
Log in

Late-Onset Ankylosing Spondylitis and Related Spondylarthropathies

Clinical and Radiological Characteristics and Pharmacological Treatment Options

  • Leading Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Ankylosing spondylitis is the prototype of related diseases commonly called spondylarthropathies which include reactive arthritis, psoriatic arthritis, arthritis associated with inflammatory bowel diseases (enteropathic arthritis) and undifferentiated spondylarthropathies. Ankylosing spondylitis and spondylarthropathies are generally observed in young patients but can be observed later in life or in persons >50 years of age. All the spondylarthropathy subgroups are represented in the elderly with some features particular to this age group. Indeed, radiological aspects of ankylosing spondylitis may be difficult to interpret because of the radiological changes induced by aging. Late-onset peripheral spondylarthropathies are characterised by severe disease, marked elevation of laboratory parameters of inflammation, oligoarthritis involving the lower limbs and oedema of the extremities. Psoriatic arthritis is more severe in the elderly and is associated with worse outcomes than in young patients. The clinical presentation of undifferentiated spondylarthropathy is as varied in the elderly as in young and middle-aged adults. Reactive arthritis and enteropathic arthritis are observed in the elderly more rarely.

The effects of aging on drug metabolism and pharmacokinetics, together with the existence of co-morbidities and polypharmacy, are responsible for difficulties in the therapeutic management of late-onset ankylosing spondylitis or spondylarthropathies. Indeed, NSAIDs should be used with caution in older patients because of the high risk of serious gastrointestinal complications. Sulfasalazine and methotrexate have been used as disease-controlling drugs but did not prove very effective. Pamidronate and tumour necrosis factor (TNF)-α antagonists offer a therapeutic alternative but have not been specifically tested in the elderly. Pamidronate has been tested in young-onset ankylosing spondylitis and spondylarthropathies with conflicting results but can be used in older patients without risk of major adverse effects. TNFα antagonists have been adequately evaluated in ankylosing spondylitis and spondylarthropathies and are associated with dramatic improvement in clinical and biological parameters of disease activity. However, the safety profile of these agents in the elderly is not currently known and careful surveillance, in particular for the risk of infection such as tuberculosis, and/or exacerbation of chronic heart failure, is thus required when using these drugs in this age group.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Wollheim FA. Ankylosing spondylitis. In: Kelley WN, Harris ED, Ruddy S, editors. Textbook of rheumatology. Philadelphia (PA): Saunders 1993: 943–55

    Google Scholar 

  2. Van Der Linden S, Van Der Heijde D. Ankylosing spondylitis: clinical features. Rheum Dis Clin North Am 1998; 24: 663–76

    Article  PubMed  Google Scholar 

  3. Brown MA, Kennedy LG, MacGregor AJ, et al. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthritis Rheum 1997; 40: 1823–8

    Article  PubMed  CAS  Google Scholar 

  4. Calin A. Terminology, introduction, diagnostic criteria and overview. In: Calin A, Taurog JD, editors. The spondylarthritides. Oxford: Oxford University Press, 1998: 1–15

    Google Scholar 

  5. Saraux A, Guedes C, Allain J, et al. Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France. J Rheumatol 1999; 26: 2622–7

    PubMed  CAS  Google Scholar 

  6. Guillemin F, Saraux A, Guggenbuhl P, et al. Prévalence de la polyarthrite rhumatoïde et des spondylarthropathies en France en 2001. Rev Rhum [Ed Fr] 2002; 69: 1014

    Article  Google Scholar 

  7. Gran JT, Skomsvoll JF. The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol 1997; 36: 766–71

    Article  PubMed  CAS  Google Scholar 

  8. Boonen A. Socioeconomic consequences of ankylosing spondylitis. Clin Exp Rheumatol 2002; 20Suppl. 28: S23–6

    PubMed  CAS  Google Scholar 

  9. Amor B, Santos RS, Nahal R, et al. Predictive factors for the longterm outcome of spondylarthropathies. J Rheumatol 1994; 21: 1883–7

    PubMed  CAS  Google Scholar 

  10. Braun J, Pincus T. Mortality, course of the disease and prognosis of patients with ankylosing spondylitis. Clin Exp Rheumatol 2002; 20Suppl. 28: S16–22

    PubMed  CAS  Google Scholar 

  11. Gran JT, Husby G. Ankylosing spondylitis: current drug treatment. Drugs 1992; 44: 585–603

    Article  PubMed  CAS  Google Scholar 

  12. Creemers MCW, Van Riel PCLM, Franssen MJAM. Second-line treatment in seronegative spondylarthropathies. Semin Arthritis Rheum 1994; 24: 71–81

    Article  PubMed  CAS  Google Scholar 

  13. Toussirot E, Wendling D. Current guidelines for the drug treatment of ankylosing spondylitis. Drugs 1998; 56: 225–40

    Article  PubMed  CAS  Google Scholar 

  14. Wendling, Toussirot E. Anti-TNFα therapy in ankylosing spondylitis. Exp Opin Pharmacother 2004; 5: 1497–507

    Article  CAS  Google Scholar 

  15. Dubost JJ, Sauvezie B. Actualités des rhumatismes inflammatoires du sujet âgé. Rev Rhum 1992; 59 (6 bis): 38S–42S

    Google Scholar 

  16. Amor B, Bouchet H, Delrieu F. Enquête nationale sur les arthrites réactionnelles de la Société Française de Rhumatologie. Rev Rhum 1983; 50: 733–43

    PubMed  CAS  Google Scholar 

  17. Carbone LD, Cooper C, Michet CJ, et al. Ankylosing spondylitis in Rochester, Minnesota 1935–1989: is the epidemiology changing? Arthritis Rheum 1992; 35: 1476–82

    Article  PubMed  CAS  Google Scholar 

  18. Feldtkeller E, Bruckel J, Khan MA. Scientific contributions of ankylosing spondylitis patient advocacy groups. Curr Opin Rheumatol 2000; 12: 239–47

    Article  PubMed  CAS  Google Scholar 

  19. Dubost JJ, Ristori JM, Zmantar C, et al. Rhumatismes séronégatifs à début Tardif: fréquence et atypie des spondylarthropathies. Rev Rhum 1991; 58: 577–84

    PubMed  CAS  Google Scholar 

  20. Van der Linden SM, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361–8

    Article  PubMed  Google Scholar 

  21. Dubost JJ, Sauvezie B. Late onset peripheral spondylarthropathy. J Rheumatol 1989; 16: 1214–7

    PubMed  CAS  Google Scholar 

  22. Caplanne D, Tubach F, Le Parc JM. Late onset spondylarthropathy: clinical and biological comparison with early onset patients. Ann Rheum Dis 1997; 56: 176–9

    Article  PubMed  CAS  Google Scholar 

  23. Olivieri I, Padula A, Pierro A, et al. Late onset seronegative spondylarthropathy. J Rheumatol 1995; 22: 899–903

    PubMed  CAS  Google Scholar 

  24. Kay LJ, Walker DJ. Late onset spondylarthropathy: comparison with early onset patient [letter]. Ann Rheum Dis 1997; 57: 572

    Article  Google Scholar 

  25. Amor B, Dougados M, Mijiyama M. Critères de classification des spondylarthropathies. Rev Rhum 1990; 57: 85–9

    PubMed  CAS  Google Scholar 

  26. Garrett S, Jenkinson T, Whitelock H, et al. A new approach to defining disease status in AS: the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). J Rheumatol 1994; 21: 2286–91

    PubMed  CAS  Google Scholar 

  27. Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index (BASFI). J Rheumatol 1994; 21: 2281–5

    PubMed  CAS  Google Scholar 

  28. Brophy S, Calin A. Ankylosing spondylitis: interaction between genes, joints, age at onset and disease expression. J Rheumatol 2001; 28: 2283–8

    PubMed  CAS  Google Scholar 

  29. Kaipiainen-Seppanen O. Incidence of psoriatic arthritis in Finland. Br J Rheumatol 1996; 35: 1289–91

    Article  PubMed  CAS  Google Scholar 

  30. Punzi L, Pianon M, Rossini P, et al. Clinical and laboratory manifestations of elderly onset psoriatic arthritis: a comparison with younger onset disease. Ann Rheum Dis 1999; 58: 226–9

    Article  PubMed  CAS  Google Scholar 

  31. Dougados M, Van Der Linden S, Juhlin R, et al. The European Spondylarthropathy Study Group: the European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991; 34: 1218–27

    Article  PubMed  CAS  Google Scholar 

  32. McCarty DJ, O’Duffy JD, Pearson L, et al. Remitting synovitis seronegative symmetric synovitis with pitting edema (RS3PE) syndrome. JAMA 1985; 254: 2763–7

    Article  PubMed  CAS  Google Scholar 

  33. Cantini F, Salvanari C, Olivieri I, et al. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome: a prospective follow-up and magnetic resonance imaging study. Ann Rheum Dis 1999; 58: 230–6

    Article  PubMed  CAS  Google Scholar 

  34. Ponce A, Sanmarti R, Orellana C, et al. Spondylarthropathy presenting as polymyalgia rheumatica-like syndrome. Clin Rheumatol 1997; 16: 614–6

    Article  PubMed  CAS  Google Scholar 

  35. Olivieri I, Salvanari C, Cantini F, et al. Ankylosing spondylitis and undifferentiated spondylarthropathies: a clinical review and description of a disease subset with older age at onset. Curr Opin Rheumatol 2001; 13: 280–4

    Article  PubMed  CAS  Google Scholar 

  36. Koeger AC, Karmochkine M, Chaïbi P. RS3PE syndrome associated with advanced ankylosing spondylitis. J Rheumatol 1995; 22(2): 375–6

    PubMed  CAS  Google Scholar 

  37. Anderson JJ, Baron G, Van Der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001; 44: 1876–86

    Article  PubMed  CAS  Google Scholar 

  38. Wanders A, Van Der Heijde D, Landewé R, et al. Inhibition of radiographic progression in ankylosing spondylitis by continuous use of NSAIDs. Arthritis Rheum 2003; 48Suppl. 1: S233

    Google Scholar 

  39. Buffum M, Buffum JC. Non steroidal antiinflammatory drugs in the elderly. Pain Manag Nurs 2000; 1: 40–50

    Article  PubMed  CAS  Google Scholar 

  40. Greenwald DA. Aging, the gastrointestinal tract, and the risk of acid related disease. Am J Med 2004; 117(5A): 8S–13S

    PubMed  Google Scholar 

  41. Nikolaus T, Zeyfang A. Pharmacological treatments for persistent non-malignant pain in older persons. Drugs Aging 2004; 21: 19–41

    Article  PubMed  CAS  Google Scholar 

  42. Montamat SC, Cusack BJ, Vestal RE. Management of drug therapy in the elderly. N Engl J Med 1989; 321: 303–9

    Article  PubMed  CAS  Google Scholar 

  43. Lee M, Feldman M. The aging stomach: implications for NSAID gastropathy. Gut 1997; 41: 425–6

    Article  PubMed  CAS  Google Scholar 

  44. Davis MP, Srivastava M. Demographics, assessment and management of pain in the elderly. Drugs Aging 2003; 20: 23–57

    Article  PubMed  CAS  Google Scholar 

  45. Beyth R, Shorr RI. Epidemiology of adverse drug reactions in the elderly by drug class. Drugs Aging 1999; 14: 231–9

    Article  PubMed  CAS  Google Scholar 

  46. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl 1999; 56: 18–24

    PubMed  CAS  Google Scholar 

  47. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 294: 1247–55

    Article  Google Scholar 

  48. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR study group. N Engl J Med 2000; 343: 1520–8

    Article  PubMed  CAS  Google Scholar 

  49. Dougados M, Behier J, Jolchine I, et al. Efficacy of celecoxib, a COX-2 specific inhibitor in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against conventional nonsteroidal anti-inflammatory drug. Arthritis Rheum 2001; 44: 180–5

    Article  PubMed  CAS  Google Scholar 

  50. Emery P, Baraf HS, Schiff M, et al. Etoricoxib, a COX-2 selective inhibitor in ankylosing spondylitis patients with poor response to non steroidal anti-inflammatory drugs [abstract]. Ann Rheum Dis 2004; 63Suppl. 1: 99

    Google Scholar 

  51. Bennett WM. Drug-related renal dysfunction. Geriatr Nephrol Urol 1999; 9: 21–5

    Article  PubMed  CAS  Google Scholar 

  52. Marzo-Ortega H, Emery P, McGonagle D. The concept of disease modification in spondylarthropathy. J Rheumatol 2002; 29: 959–65

    Google Scholar 

  53. Dougados M, Van Der Linden S, Leirisalo-Repo M, et al. Sulfasalazine in the treatment of spondylarthropathy: a randomized, multicenter, double blind, placebo-controlled study. Arthritis Rheum 1995; 38: 618–27

    Article  PubMed  CAS  Google Scholar 

  54. Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of seronegative spondylarthropathies: a Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1999; 42: 2325–9

    Article  PubMed  CAS  Google Scholar 

  55. Bosi-Ferraz M, Tugwell P, Goldsmith C, et al. Meta-analysis of sulfasalazine in ankylosing spondylitis. J Rheumatol 1990; 17: 1782–6

    Google Scholar 

  56. Gardner G, Furst DE. Disease-modifying antirheumatic drugs: potential effects in older patients. Drugs Aging 1995; 7: 420–37

    Article  PubMed  CAS  Google Scholar 

  57. Creemers MCW, Franssen MJ, Van De Putte LBA, et al. Methotrexate in severe ankylosing spondylitis: an open study. J Rheumatol 1995; 22: 1104–7

    PubMed  CAS  Google Scholar 

  58. Biasi D, Carletto A, Carmaschi P, et al. Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study. Clin Rheumatol 2000; 19: 114–7

    Article  PubMed  CAS  Google Scholar 

  59. Sampaio-Barros PD, Costallat LTL, Bertolo M, et al. Methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 2000; 29: 160–2

    Article  PubMed  CAS  Google Scholar 

  60. Altan L, Bingol U, Karakoc Y, et al. Clinical investigation of methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 2001; 30: 255–9

    Article  PubMed  CAS  Google Scholar 

  61. Chepeleva SN, Sigidin YA, Loukina GV. The results of the comparative study of sulphasalazine and methotrexate in ankylosing spondylitis [abstract]. Ann Rheum Dis 2002; 61Suppl. 1: 299–300

    Google Scholar 

  62. Gonzalez-Lopez L, Garcia-Gonzalez A, Vasquez-Del-Mercado M, et al. Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial. J Rheumatol 2004; 31: 1568–74

    PubMed  CAS  Google Scholar 

  63. Tett SE, Triggs EJ. Use of methotrexate in older patients: a risk benefit assessment. Drugs Aging 1996; 9: 458–71

    Article  PubMed  CAS  Google Scholar 

  64. Rheumatoid Arthritis Clinical Trial Archive Group. The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. J Rheumatol 1995; 22: 218–23

    Google Scholar 

  65. Nash P, Clegg DO. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis 2005; 64Suppl. 2: ii4–7

    Google Scholar 

  66. Fleisch H. Bisphosphonates: preclinical. In: Fleisch III H, editor. Bisphosphonates in bone disease: from the laboratory to the patient. New York: Parthenon Publishing Group, 1997: 32–57

    Google Scholar 

  67. Dunn CJ, Galinet LA, Wu H, et al. Demonstration of novel antiarthritic and anti-inflammatory effects of diphosphonates. J Pharmacol Exp Ther 1993; 266: 1691–8

    PubMed  CAS  Google Scholar 

  68. Maksymowych WP. Bisphosphonates: anti-inflammatory properties. Curr Med Chem Antiinflammatory Anti Allergic Agents 2002; 1: 15–28

    Article  CAS  Google Scholar 

  69. Redlich K, Hayer S, Maier A, et al. Tumor necrosis factor alpha mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 2002; 46: 785–92

    Article  PubMed  CAS  Google Scholar 

  70. Hasegawa J, Nagashima M, Yamamoto M, et al. Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritis. J Rheumatol 2003; 30: 474–9

    PubMed  CAS  Google Scholar 

  71. Haibel H, Braun J, Maksymowych WP. Bisphosphonates: targeting bone in the treatment of spondyloarthritis. Clin Exp Rheumatol 2002; 20Suppl. 28: S162–S66

    PubMed  CAS  Google Scholar 

  72. Maksymowych WP. Bisphosphonates for arthritis: a confusing rationale. J Rheumatol 2003; 30: 430–4

    PubMed  Google Scholar 

  73. Maksymowych WP, Jhangri GS, Leclercq S, et al. An open study of pamidronate in the treatment of refractory ankylosing spondylitis. J Rheumatol 1998; 25: 714–7

    PubMed  CAS  Google Scholar 

  74. Maksymowych WP, Lambert R, Jhangri GS, et al. Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy. J Rheumatol 2001; 28: 144–55

    PubMed  CAS  Google Scholar 

  75. Maksymowych WP, Jhangri GS, Fitzgerald AA, et al. A six-month randomized, controlled, double-blind, dose response comparison of intravenous pamidronate (60mg versus 10mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002; 46: 766–73

    Article  PubMed  CAS  Google Scholar 

  76. Haibel H, Brandt J, Rudwaleit M, et al. Treatment of active ankylosing spondylitis with pamidronate. Rheumatology 2003; 42: 1018–20

    Article  PubMed  CAS  Google Scholar 

  77. Toussirot E, Lohse A, Le Huédé G, et al. Treatment of refractory and active spondylarthropathies with pamidronate: an open study [abstract]. Ann Rheum Dis 2004; 63Suppl. 1: 395

    Google Scholar 

  78. Toussirot E, Wendling D. Bone mass in ankylosing spondylitis. Clin Exp Rheumatol 2000; 18Suppl. 21: S16–20

    Google Scholar 

  79. Cairns AP, Wright SA, Taggart AJ, et al. An open study of pulse pamidronate therapy in severe ankylosing spondylitis and its effects on biochemical marker of bone turnover. Ann Rheum Dis 2005; 64: 338–9

    Article  PubMed  CAS  Google Scholar 

  80. Braun J, Bollow M, Neure L, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38: 499–505

    Article  PubMed  CAS  Google Scholar 

  81. Gratacos J, Collado A, Filella X, et al. Serum cytokines (IL-6, TNFα, IL-1β and IFNγ) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 1994; 33: 927–31

    Article  PubMed  CAS  Google Scholar 

  82. Sandborn WJ. Anti-tumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results and safety. Inflamm Bowel Dis 1999; 5: 119–33

    Article  PubMed  CAS  Google Scholar 

  83. Toussirot E, Wendling D. The use of TNF-α blocking agents in rheumatoid arthritis: an overview. Expert Opin Pharmacother 2004; 5: 581–94

    Article  PubMed  CAS  Google Scholar 

  84. Markham A, Lamb HM. Infliximab. A review of its use in the management of rheumatoid arthritis. Drugs 2000; 59: 1341–59

    Article  PubMed  CAS  Google Scholar 

  85. Etanercept: soluble tumour necrosis factor receptor, TNF receptor fusion protein, TNFR-Fc, TNR001, Enbrel. Drugs R D 1999; 1: 258–61

  86. Machold KP, Smolen JS. Adalimumab: a new TNFα antibody for the treatment of inflammatory joint disease. Expert Opin Biol Ther 2003; 3: 351–60

    PubMed  CAS  Google Scholar 

  87. Braun J, De Keyser F, Brandt J, et al. New treatment option in spondylarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy. Curr Opin Rheumatol 2001; 13: 245–9

    Article  PubMed  CAS  Google Scholar 

  88. Sieper J, Braun J. New treatment options in ankylosing spondylitis: a role for anti-TNFα therapy. Ann Rheum Dis 2001; 60Suppl. 3: iii58–61

    PubMed  CAS  Google Scholar 

  89. Van Den Bosch F, Baeten D, Kruithof E, et al. Treatment of active spondylarthropathy with infliximab, the chimeric monoclonal antibody to tumor necrosis factor alpha. Ann Rheum Dis 2001; 60Suppl. 3: iii33–66

    PubMed  Google Scholar 

  90. Brandt J, Haibel H, Comely D, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor α monoclonal antibody infliximab. Arthritis Rheum 2000; 43: 1346–52

    Article  PubMed  CAS  Google Scholar 

  91. Van Der Bosch F, Kruithof E, Baeten D, et al. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) in spondylarthropathy: an open pilot study. Ann Rheum Dis 2000; 59: 428–33

    Article  PubMed  Google Scholar 

  92. Stone M, Salonen D, Lax M, et al. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J Rheumatol 2001; 28: 1605–14

    PubMed  CAS  Google Scholar 

  93. Kruithof E, Van Den Bosch F, Baeten D, et al. Repeated infusions of infliximab, a chimeric anti-TNFα monoclonal antibody in patients with active spondylarthropathy: one year follow up. Ann Rheum Dis 2002; 61: 207–12

    Article  PubMed  CAS  Google Scholar 

  94. Maksymowych W, Jhangri GS, Lambert RG, et al. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 2002; 29: 959–65

    PubMed  CAS  Google Scholar 

  95. Breban M, Vignon E, Claudepierre P, et al. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology 2002; 41: 1280–5

    Article  PubMed  CAS  Google Scholar 

  96. Braun J, Brandt J, Listing J, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three month, randomized, placebo-controlled trial. Arthritis Rheum 2003; 48: 2224–33

    Article  PubMed  CAS  Google Scholar 

  97. Temekonidis TI, Alamanos Y, Nikas SN, et al. Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study. Ann Rheum Dis 2003; 62: 1218–20

    Article  PubMed  CAS  Google Scholar 

  98. Collantes-Estevez E, Munoz-Villanueva MC, Canete-Crespillo JD, et al. Infliximab in refractory spondylarthropathies: a multicentre 38 week open study. Ann Rheum Dis 2003; 62: 1239–40

    Article  PubMed  CAS  Google Scholar 

  99. Marzo-Ortega H, McGonagle D, O’Connor D, et al. Efficacy of etanercept in the treatment of entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum 2001; 44: 2112–7

    Article  PubMed  CAS  Google Scholar 

  100. Brandt J, Khariouzov A, Listing J, et al. Successful short term treatment of patients with severe undifferentiated spondylarthritis with the anti-tumor necrosis factor-α fusion receptor protein etanercept. J Rheumatol 2004; 31: 531–8

    PubMed  CAS  Google Scholar 

  101. Van Den Bosch F, Kruithof E, Baeten D, et al. Randomised double blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002; 46: 755–65

    Article  CAS  Google Scholar 

  102. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet 2002; 359: 1187–93

    Article  PubMed  CAS  Google Scholar 

  103. Gorman J, Sack KE, Davis Jr JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002; 346: 1349–56

    Article  PubMed  CAS  Google Scholar 

  104. Davis JC, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48: 3230–6

    Article  PubMed  CAS  Google Scholar 

  105. Rudwaleit M, Listing J, Brandt J, et al. Prediction of a major clinical response (BASDAI) to tumour necrosis factor α blockers in ankylosing spondylitis. Ann Rheum Dis 2004; 63: 665–70

    Article  PubMed  CAS  Google Scholar 

  106. Veale DJ, Ritchlin C, Fitzgerald O. Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis 2005; 64Suppl. 2: ii26–9

    Article  PubMed  Google Scholar 

  107. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385–90

    Article  PubMed  CAS  Google Scholar 

  108. Mease PJ, Ruderman EM, Ritchlin CT, et al. Etanercept in psoriatic arthritis: sustained improvement in joint and skin disease and inhibition of radiographic progression at 2 years [abstract]. Ann Rheum Dis 2004; 63Suppl. 1: 99

    Google Scholar 

  109. Yazici Y, Erkan D, Lockshin MD. A preliminary study of etanercept in the treatment of severe, resistant psoriatic arthritis. Clin Exp Rheumatol 2000; 18: 732–4

    PubMed  CAS  Google Scholar 

  110. Antoni C, Kavanaugh A, Kirkham B, et al. The one year results of the infliximab multinational psoriatic arthritis controlled trial (IMPACT) [abstract]. Arthritis Rheum 2003; 48Suppl. 1: 603

    Google Scholar 

  111. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor a therapy. Arthritis Rheum 2003; 48: 3013–22

    Article  PubMed  CAS  Google Scholar 

  112. Kroesen S, Widmer AF, Tyndall A, et al. Serious bacterial infections in patients with rheumatoid arthritis under anti TNFα therapy. Rheumatology 2003; 42: 617–21

    Article  PubMed  CAS  Google Scholar 

  113. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor neutralizing agent. N Engl J Med 2001; 345: 1098–104

    Article  PubMed  CAS  Google Scholar 

  114. Salmon-Ceron D, on behalf of the Group RATIO and AFSSAPS. Recommendations for the prevention and management of tuberculosis in patients taking infliximab. Ann Med Interne (Paris) 2002; 153: 429–31

    CAS  Google Scholar 

  115. Baeten D, Kruithof E, Van Den Bosch F, et al. Systematic safety follow up in a cohort of 107 patients with spondylarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 2003; 62: 829–34

    Article  PubMed  CAS  Google Scholar 

  116. Shibata A, Zhao S, Makuch RW, et al. Lymphoma risk in ankylosing spondylitis patients is greater than that observed in the general population [abstract]. Ann Rheum Dis 2004; 63Suppl. 1: 98

    Google Scholar 

  117. Kwon HJ, Cote TR, Cuffe MS, et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003; 20: 807–11

    Google Scholar 

  118. Hyrich KL, Silman AJ, Watson KD, et al. Anti-tumour necrosis factor α therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis 2004; 63: 1538–43

    Article  PubMed  CAS  Google Scholar 

  119. Cairns A, Taggart A. Anti-tumour necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland. Ulster Med J 2002; 71: 101–5

    PubMed  CAS  Google Scholar 

  120. Chevillotte-Maillard H, Ornetti P, Mistrih R, et al. Survival and safety of treatment with infliximab in the elderly population. Rheumatology (Oxford) 2005; 44: 695–6

    Article  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Department of Rheumatology, University Hospital Jean Minjoz, Bd Fleming, F-25030, Besançon, France

    Éric Toussirot & Daniel Wendling

Authors
  1. Éric Toussirot
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel Wendling
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Éric Toussirot.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Toussirot, É., Wendling, D. Late-Onset Ankylosing Spondylitis and Related Spondylarthropathies. Drugs Aging 22, 451–469 (2005). https://doi.org/10.2165/00002512-200522060-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200522060-00001

Keywords

Search

Navigation